Individuals revert to their original weight and forfeit every cardiometabolic advantage within fewer than two years after discontinuing semaglutide or tirzepatide, as uncovered by a recent meta-analysis.
Real-world data suggests that roughly half of individuals with obesity cease use of GLP-1 receptor agonists within one year of starting, making it crucial to understand body weight changes post-treatment cessation, noted Sam West, a postdoctoral researcher in the Nuffield Department of Primary Care Health Sciences at the University of Oxford in England, along with his team in their publication dated January 7, 2026, in The BMJ.
The findings, derived from 9341 individuals across 37 investigations covering various weight-reduction drugs including older options, indicated a return to initial weight on average after 1.7 years. The typical monthly weight regain stood at 0.4 kg, roughly four times quicker than following behavioral approaches, irrespective of the original weight shed. Projected cardiometabolic improvements were expected to revert to baseline levels even faster upon halting GLP-1s.
These medications prove highly potent and serve as a key resource in addressing obesity, yet obesity represents a recurring chronic issue. It's evident that ongoing management or therapeutic measures must persist to uphold the advantages of such therapies, remarked co-author Susan Jebb, PhD, OBE, a professor of Diet and Population Health at the same Oxford institution, in a briefing organized by the Science Media Centre.
Jebb elaborated that these pharmaceuticals should be viewed as a single choice among broader obesity management strategies. They do not constitute the sole approach to obesity care. To optimize value for the UK's National Health Service (NHS), selecting the appropriate intervention for the suitable individual at the ideal moment is vital, given the vast population that stands to gain.
In a related editorial, Qi Sun, MD, an associate professor of medicine at Brigham and Women's Hospital and Harvard Medical School in Boston, stated that GLP-1 receptor agonists cannot be depended upon as a miraculous solution for obesity. Although notable, even temporary weight reduction can offer certain health perks for those with obesity, users of these drugs ought to recognize the elevated discontinuation likelihood and the fallout from medication cessation. Sound eating habits and lifestyle choices must form the cornerstone of obesity prevention and control, with pharmaceuticals like GLP-1s acting as supplementary aids. These habits not only avert unwarranted weight accumulation but also deliver extensive health advantages extending past mere weight management.
The research highlights that weight regain intensifies upon drug discontinuation, observed Adam Collins, PhD, from the University of Surrey in England, noting that preserving weight loss poses a significant hurdle.
Artificially elevating GLP-1 levels might lead to diminished natural production in patients. This poses no issue during medication use, but upon withdrawal of this GLP-1 boost, appetite remains unchecked, raising the odds of excessive eating. Similar to an individual overcoming addiction abruptly, this transition proves daunting. The difficulty heightens if the person depended exclusively on GLP-1 for appetite suppression without adopting lasting dietary or behavioral modifications to sustain long-term progress, Collins further explained.
What Occurs Upon Ceasing Weight-Reduction Drugs?
In the examined studies, all treatments lasted at least 8 weeks, with monitoring spanning a minimum of 4 weeks, involving adults who were overweight or obese. The group included 6322 treatment participants and 3019 controls. Treatment typically extended 10 months, followed by 8 months of observation.
Participants shed an average of 8.3 kg during therapy but recovered 4.8 kg within one year, at a monthly pace of 0.4 kg. They reached their starting weight around 1.7 years after ending treatment.
